Theoretical concerns about drug ring true but many questions remain unanswered.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Sheridan, C. Third Tysabri adverse case hits drug class. Nat Rev Drug Discov 4, 357–358 (2005). https://doi.org/10.1038/nrd1743
Issue Date:
DOI: https://doi.org/10.1038/nrd1743
This article is cited by
-
RNAi-based therapeutic strategies for metabolic disease
Nature Reviews Endocrinology (2011)
-
Case histories, magic bullets and the state of drug discovery
Nature Reviews Drug Discovery (2006)
-
The problem with potency
Nature Biotechnology (2005)
-
Natalizumab and PML
Nature Neuroscience (2005)